Table 2.
Diabetes Medication and other Factors During Trajectory Associated with Weight-change Patterns
| Characteristic | Weight-change pattern | ||||
|---|---|---|---|---|---|
| Higher stable weight | Lower stable weight | Weight gain | Weight loss | P value* | |
| N | 757 | 2,236 | 664 | 478 | |
| DM medication class# | |||||
| Sulfonylureas (SU)‡, N (%) | 214 (28.3) | 589 (26.3) | 260 (39.2) | 95 (19.9) | <0.001§ |
| Metformin ║, N (%) | 107 (14.1) | 287 (12.8) | 51 (7.7) | 92 (19.3) | <0.001§ |
| SU and metformin¶, N (%) | 64 (8.5) | 161 (7.2) | 110 (16.6) | 19 (4.0) | <0.001§ |
| Insulin†, N (%) | 6 (0.8) | 25 (1.1) | 15 (2.3) | 5 (1.1) | 0.062 |
| Thiazolidinedione#, N (%) | 1 (0.13) | 1 (0.04) | 1 (0.15) | 0 | 0.679 |
| Acarbose#, N (%) | 2 (0.26) | 5 (0.22) | 3 (0.45) | 0 | 0.490 |
| Repaglinide#, N (%) | 0 | 1 (0.04) | 0 | 0 | 0.838 |
| No DM medication, n (%) | 370 (48.9) | 1,191 (53.3) | 241 (36.3) | 270 (56.5) | <0.001§ |
| Nutrition visits (any), n (%) | 132 (17.4) | 432 (19.3) | 111 (16.7) | 110 (23.0) | 0.04§ |
| Endocrinology visits, mean ± SD | 0.04 ± 0.4 | 0.05 ± 0.4 | 0.06 ± 0.4 | 0.05 ± 0.4 | 0.692 |
| Primary care visits mean ± SD | 4.2 ± 3.8 | 4.1 ± 3.7 | 5.0 ± 4.4 | 3.7 ± 3.5 | <0.001§ |
| Quit smoking, n (%) | 24 (3.2) | 46 (2.1) | 32 (4.8) | 9 (1.9) | 0.001§ |
*Comparison across all four groups
†Any use of insulin during year 1
‡Received >30 days of SU during year 1
§Comparison of weight-gain compared to weight-loss groups also significant at p < 0.05
║Received >30 days of metformin during year 1
¶Received >30 days of SU and metformin during year 1
#Received >30 days of thiazolidinedione (TZDs), or acarbose, or repaglinide during year 1